Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1299 participants.

Also called NCT01387737

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,299 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01387737
Other papers using this trial's data
  • Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus Advances in therapy, 2015-11 DOI, PubMed 26530268, PMC4662712 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01387737. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-04-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TA-7284-Low
Intervention (Drug)
TA-7284-High
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct01387737
Content hash
59a01b2bc701ada5e413cd8cf3e9e5aab6185199cd7a32a211fb0477140ec2b5